Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects

NCT05737485 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Ciliary Dyskinesia

Interventions

DRUG: RCT1100

Sponsor

ReCode Therapeutics